Pengyu Huang

Pengyu Huang

Auto-generated profile, based on publicly available information

Pengyu Huang

State Key Laboratory of Advanced Medical Materials and Devices, Engineering Research Center of Pulmonary and Critical Care Medicine Technology and Device (Ministry of Education), Tianjin Key Laboratory of Biomedical Materials, Institute of Biomedical Engineering, Tianjin Institutes of Health Science, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin 300192, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2018 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
HZHaibo Zhou
Haibo Zhou
JLJunlai Liu
Junlai Liu
CZChangyang Zhou
Changyang Zhou
NGNi Gao
Ni Gao
ZRZhiping Rao
Zhiping Rao
HYHui Yang
Hui Yang

20 May 2020 in Gut
Verified
Journal Article
Open access
PDF file
HYHuayu Yang
Huayu Yang
LSLejia Sun
Lejia Sun
YPYuan Pang
Yuan Pang
DHDandan Hu
Dandan Hu
HXHaifeng Xu
Haifeng Xu
YMYilei Mao
Yilei Mao
Objective: Shortage of organ donors, a critical challenge for treatment of end-stage organ failure, has motivated the development of alternative strategies to generate organs in vitro. Here, we aim to describe the hepatorganoids, which is a liver tissue model generated by three-dimensional (3D) bioprinting of HepaRG cells and investigate its liver functions in vitro and in vivo. Design: 3D bioprinted hepatorganoids (3DP-HOs) were constructed using HepaRG cells and bioink, according to specific 3D printing procedures. Liver functions of 3DP-HOs were detected after 7 days of differentiation in vitro, which were later transplanted into Fah-deficient mice. The in vivo liver functions of 3DP-HOs were evaluated by survival time and liver damage of mice, human liver function markers and human-specific debrisoquine metabolite production. Results: 3DP-HOs broadly acquired liver functions, such as ALBUMIN secretion, drug metabolism and glycogen storage after 7 days of differentiation. After transplantation into abdominal cavity of Fah -/- Rag2 -/- mouse model of liver injury, 3DP-HOs further matured and displayed increased synthesis of liver-specific proteins. Particularly, the mice acquired human-specific drug metabolism activities. Functional vascular systems were also formed in transplanted 3DP-HOs, further enhancing the material transport and liver functions of 3DP-HOs. Most importantly, transplantation of 3DP-HOs significantly improved the survival of mice. Conclusions: Our results demonstrated a comprehensive proof of principle, which indicated that 3DP-HO model of liver tissues possessed in vivo hepatic functions and alleviated liver failure after transplantation, suggesting that 3D bioprinting could be used to generate human liver tissues as the alternative transplantation donors for treatment of liver diseases.

1 January 2021 in Biomaterials
Verified
Journal Article
Closed access
FXFeihu Xie
Feihu Xie
LSLejia Sun
Lejia Sun
YPYuan Pang
Yuan Pang
GXGang Xu
Gang Xu
BJBao Jin
Bao Jin
YMYilei Mao
Yilei Mao

18 March 2020 in Protein & Cell
Verified
Journal Article
Open access
PDF file
BHBingbing He
Bingbing He
WPWenbo Peng
Wenbo Peng
JHJia Huang
Jia Huang
HZHang Zhang
Hang Zhang
YZYingsi Zhou
Yingsi Zhou
PHPengyu Huang
Pengyu Huang

1 June 2017 in EBioMedicine
Verified
Journal Article
Open access
XYXuan Yao
Xuan Yao
XWXing Wang
Xing Wang
JLJunlai Liu
Junlai Liu
XHXinde Hu
Xinde Hu
LSLinyu Shi
Linyu Shi
HYHui Yang
Hui Yang
Precisely targeted genome editing is highly desired for clinical applications. However, the widely used homology-directed repair (HDR)-based genome editing strategies remain inefficient for certain in vivo applications. We here demonstrate a microhomology-mediated end-joining (MMEJ)-based strategy for precisely targeted gene integration in transfected neurons and hepatocytes in vivo with efficiencies up to 20%, much higher (up to 10 fold) than HDR-based strategy in adult mouse tissues. As a proof of concept of its therapeutic potential, we demonstrate the efficacy of MMEJ-based strategy in correction of Fah mutation and rescue of Fah-/- liver failure mice, offering an efficient approach for precisely targeted gene therapies.

19 April 2021 in Cell Discovery
Verified
Journal Article
Open access
PDF file
HWHeming Wang
Heming Wang
RHRong Huang
Rong Huang
LLLing Li
Ling Li
JZJunjin Zhu
Junjin Zhu
ZLZhihong Li
Zhihong Li
PHPengyu Huang
Pengyu Huang
High-throughput sequencing reveals the complex landscape of small noncoding RNAs (sRNAs). However, it is limited by requiring 5′-monophosphate and 3′-hydroxyl in RNAs for adapter ligation and hindered by methylated nucleosides that interfere with reverse transcription. Here we develop Cap-Clip acid pyrophosphatase (Cap-Clip), T4 polynucleotide kinase (PNK) and AlkB/AlkB(D135S)-facilitated small ncRNA sequencing (CPA-seq) to detect and quantify sRNAs with terminus multiplicities and nucleoside methylations. CPA-seq identified a large number of previously undetected sRNAs. Comparison of sRNAs with or without AlkB/AlkB(D135S) treatment reveals nucleoside methylations on sRNAs. Using CPA-seq, we profiled the sRNA transcriptomes (sRNomes) of nine mouse tissues and reported the extensive tissue-specific differences of sRNAs. We also observed the transition of sRNomes during hepatic reprogramming. Knockdown of mesenchymal stem cell-enriched U1-5′ snsRNA promoted hepatic reprogramming. CPA-seq is a powerful tool with high sensitivity and specificity for profiling sRNAs with methylated nucleosides and diverse termini.